Psilocybin
Bill To Legalize Psychedelics Passes California Senate
The California Senate has passed a bill legalizing the possession of natural psychedelics.
The post Bill To Legalize Psychedelics Passes California Senate…
The California Senate has passed a bill legalizing the possession of natural psychedelics.
Sen. Scott Wiener (D) has been pushing psychedelics bills for years, and has finally succeeded in passing this latest bill through the Senate. This latest bill was approved with a 21-16 vote yesterday and will head to the General Assembly for debate.
SB 58 legalizes specific amounts of psilocybin, psilocyn, DMT, ibogaine and mescaline. This would be for personal or facilitated use and the “possession, preparation, obtaining, transfer, as specified, or transportation…”.
The major difference between this bill and previous attempts was the exclusion of synthetic substances. Psychedelics like LSD and MDMA were not included, with a focus on natural plant entheogens making it more likely to pass the Senate.
The bill allows the following limits on psychedelic possession:
Read the full bill here and see comments from Rep Scott Weiner below.
The Senate just passed our bill (SB 58) to decriminalize possession & use of 5 naturally occurring psychedelics — psilocybin, psilocin, DMT, ibogaine, mescaline.
These substances aren’t addictive & show promise in treating mental health /addiction. Let’s stop criminalizing them.
— Senator Scott Wiener (@Scott_Wiener) May 24, 2023
The post Bill To Legalize Psychedelics Passes California Senate appeared first on Microdose.
mescaline ibogaine psilocybin mdma lsd dmt psychedelic legalize psychedelics
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
DEA resists permitting psilocybin for terminal patients under ‘Right to Try’
Red Light Holland Initiates Psilocybin Extraction Phase with PharmAla Following Successful Testing and Preparation by CCrest Labs
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psychedelics1 week agoCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week agoGoing concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week agoAre Shrooms Legal in Oregon: Full Guide
-
Law & Regulation1 week agoNuminus reports declining revenue as the company restructures
-
Psychedelics1 week ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week agoAtai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week agoPsyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation7 days agoClearmind signs agreement with Hebrew University for psychedelic compound rights